Pharmaceutical intermediates
Pazopanib Hydrochloride Intermediates
4 pharmaceutical intermediates for Pazopanib Hydrochloride. Indication: Renal cell carcinoma; Sarcoma; Soft tissue sarcoma.
About Pazopanib Hydrochloride
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Renal cell carcinoma; Sarcoma; Soft tissue sarcoma
- Approved Date
- 10/19/2009
Available intermediates
4 intermediates currently listed for Pazopanib Hydrochloride. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-Methyl-6-nitroindazole | 6494-19-5 | / | / |
| 2,3-Dimethyl-2H-indazol-6-amine hydrochloride | 635702-60-2/1444731-72-0 | / | / |
| N-(2-chloropyrimidin-4-yl)-N,2,3-trimethyl-2H-indazol-6-amine | 444731-75-3 | / | / |
| 3-Amino-6-methylbenzenesulfonamide | 9/7/6973 | / | / |
Building toward Pazopanib Hydrochloride?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →